Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 vs Cetuximab/Methotrexate in RM-SCCHN
NCT05751512Phase 3Recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of becotatug vedotin in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Lepu Biopharma Co., Ltd. Primary endpoint: Overall Survival at 24 months. Started Apr 2023; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05751512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751512.